Cover Image
市場調查報告書

Esperion Therapeutics, Inc.:產品平台分析

Esperion Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 277772
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Esperion Therapeutics, Inc.:產品平台分析 Esperion Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 29 Pages
簡介

Esperion Therapeutics, Inc.是Pfizer Inc的子公司,是總公司置於美國的生物科技企業。正在開發、商品化LDL膽固醇以及其他具有心血管系統代謝疾病風險因子的患者口服低分子治療藥。目前臨床開發中產品有心血管系統及代謝疾病風險因子患者治療藥ETC-1002、HDL模仿藥等。

本報告提供Esperion Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Esperion Therapeutics, Inc. 的基本資料

  • Esperion Therapeutics, Inc. 概要
  • 主要資訊
  • 企業資料

Esperion Therapeutics, Inc. :R&D概要

  • 主要的治療範圍

Esperion Therapeutics, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Esperion Therapeutics, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Esperion Therapeutics, Inc. :藥物簡介

  • bempedoic acid
  • 4-WF
  • ESP-41091

Esperion Therapeutics, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Esperion Therapeutics, Inc.:最近的開發平台形勢

Esperion Therapeutics, Inc.:開發暫停中的計劃

Esperion Therapeutics, Inc.:開發中止的開發中產品

Esperion Therapeutics, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07517CDB

Summary

Global Markets Direct's, 'Esperion Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Esperion Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Esperion Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Esperion Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Esperion Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Esperion Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Esperion Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Esperion Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Esperion Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Esperion Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Esperion Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Esperion Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Esperion Therapeutics, Inc. Snapshot
    • Esperion Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Esperion Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Esperion Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Esperion Therapeutics, Inc. - Pipeline Products Glance
    • Esperion Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Esperion Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Esperion Therapeutics, Inc. - Drug Profiles
    • bempedoic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 4-WF
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ESP-41091
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Esperion Therapeutics, Inc. - Pipeline Analysis
    • Esperion Therapeutics, Inc. - Pipeline Products by Target
    • Esperion Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Esperion Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Esperion Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Esperion Therapeutics, Inc. - Recent Pipeline Updates
  • Esperion Therapeutics, Inc. - Dormant Projects
  • Esperion Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ETC-276
  • Esperion Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Esperion Therapeutics, Inc., Key Information
  • Esperion Therapeutics, Inc., Key Facts
  • Esperion Therapeutics, Inc. - Pipeline by Indication, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Esperion Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Esperion Therapeutics, Inc. - Phase II, 2015
  • Esperion Therapeutics, Inc. - Preclinical, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Target, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Esperion Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Esperion Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Esperion Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Esperion Therapeutics, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Esperion Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Esperion Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Esperion Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Esperion Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top